The Food and Drug Administration approved a new use for Sunovion Pharmaceuticals' Latuda to treat schizophrenia in kids aged 13 to 17 years.
The drug was first approved in 2010 as a treatment for adults with schizophrenia, as well as adults experiencing major depressive episodes associated with bipolar I disorder.
Latuda is the first medication to be approved for adolescent patients with schizophrenia in five years, according to a news release.
More articles on supply chain:
Mylan CEO speaks out for 1st time since congressional hearing: 5 quotes
Target launches new guidelines to control chemicals in its supply chain
Shark antibodies could successfully transport drugs to brain